Supplementary materials: Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

<b>These are peer-reviewed supplementary materials for the article '</b><b>Indirect treatment comparison of </b><b>anifrolumab efficacy versus belimumab in </b><b>adults with systemic lupus erythematosus</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><br><b>Appendix A: </b><b>Systematic Literature Review</b><b>Table S1:</b> Summary of inclusion and exclusion criteria for the systematic literature review.<br><b>Appendix B: </b><b>PRISMA Flow Diagram</b><b>Figure S1: PRISMA flow diagram. </b><br><br><b>Appendix C: </b><b>Feasibility Assessment</b><b>Table S2: Overview of feasibility assessment by outcome.</b><br><b>Appendix D: </b><b>STC Analysis: Additional Details and Sensitivity Analyses</b><b>Table S3: </b>Factors adjusted in each base case STC analysis.<b>Figure S2: </b>SLEDAI reduction STC sensitivity analysis: Inclusion of MUSE<b>Figure S3: </b>SRI(4) response STC sensitivity analysis: Inclusion of MUSE<b>Figure S4: </b>BILAG flares STC sensitivity analysis: Inclusion of MUSE<b>Figure S5: </b>OCS reduction STC sensitivity analysis: Inclusion of MUSE<b>Aim: </b>Assess the comparative efficacy of anifrolumab 300 mg versus belimumab 10 mg/kg in adults with moderate-to-severe systemic lupus erythematosus (SLE) receiving standard therapy. <b>Patients and methods: </b>Population-adjusted simulated treatment comparisons (primary analyses) and matching-adjusted indirect comparisons (supporting analyses) were conducted using individual patient data from TULIP-1/TULIP-2 and summary-level data from BLISS-52/BLISS-76.<b> Results</b>: Compared with belimumab-treated patients, anifrolumab-treated patients were more than twice as likely to achieve a reduction of four or more points in SLE Disease Activity Index 2000 score (simulated treatment comparison odds ratio: 2.47; 95% CI: 1.16–5.25) and SLE Responder Index-4 response (odds ratio: 2.61; 95% CI: 1.22–5.58) at 52 weeks. <b>Conclusion: </b>Patients with moderate-to-severe SLE are more likely to achieve an improvement in disease activity with anifrolumab than with belimumab.